Sean Ekins on Muck Rack

Sean Ekins

Fuquay-Varina
As seen in: Nature, Journal of Banking Regulation, PLOS, Cell Press, Mary Ann Liebert, Inc., EIN News, Bulletin of the Atomic Scientists, Lawfare, Genetic Engineering & Biotechnology News, EIN Presswire and
#PhD, #DSc, CEO @Collabpharma, #WinningGrants #RareDiseases #BattenDisease #ML #AI #DualUse imdb.com/video/vi229230… #Jazz #UnknownKillerRobots #DrugDiscovery
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sean

Contact Sean, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Palmitoyl-protein thioesterase-1 in health and disease

|
By Morgan Barnes, Renuka Raman, Sean Ekins
| Cell Press
References 1. Koster, K.P. ∙ Yoshii, A. Depalmitoylation by palmitoyl-protein thioesterase 1 in neuronal health and degeneration Front. Synaptic Neurosci. 2019; 11:25 2. Mesquita, F.S. ... Mechanisms and functions of protein S-acylation Nat. Rev. Mol. Cell Biol. 2024; 25:488-509 3. Swarbrick, C.M.D. ... Structure, function, and regulation of thioesterases Prog. Lipid Res. 2020; 79, 101036 4. Dennis, K.M.J.H. ∙ Heather, L.C. Post-translational palmitoylation of metabolic proteins Front. Physiol.
Open in Who Shared Issue with article?

Collaborations Pharmaceuticals, Inc. demonstrates a treatment for CLN1 Batten disease crosses the blood-brain-barrier

|
By Sean Ekins
| EIN News
Collaborations Pharmaceuticals, Inc. demonstrates a treatment for CLN1 Batten disease crosses the blood-brain-barrier Collaborations Pharmaceuticals logo rhPPT1 is a recombinant protein used to treat an ultra-rare disease called Batten disease CLN1 for which there is currently no FDA approved treatment available.
Open in Who Shared View Duplicates (113) Issue with article?

Resilient pathways for drug discovery in challenging times

|
By Sean Ekins, Barbara Slusher
| Cell Press
Science & Society | Special issue: Advancing drug discoveryOnline now 1Collaborations Pharmaceuticals, Inc., Raleigh, NC 27606, USA 2Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA 3Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD, USA 4Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA 5Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore,...
Open in Who Shared Issue with article?
See all 41 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Sean

Contact Sean, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified